Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights

Area of Science:

• Oncology
• Metabolic Medicine
• Pharmacology

Background:

• Esophageal cancer (EC) presents significant treatment challenges and high mortality rates.
• Innovative therapeutic strategies are crucial for improving EC patient outcomes.
• Metformin, a common anti-diabetic medication, is being investigated for its anti-cancer properties.

Purpose of the Study:

• To systematically review and synthesize existing research on metformin's effects on esophageal cancer.
• To elucidate the metabolic and molecular mechanisms underlying metformin's potential anti-cancer activity in EC.
• To evaluate the clinical and preclinical evidence for metformin as an adjuvant therapy in EC management.

Main Methods:

• Systematic analysis of diverse scientific studies on metformin and EC.
• Comprehensive review of metabolic pathways and molecular mechanisms (e.g., insulin signaling, AMPK, mTOR).
• Critical examination of epidemiological, clinical, and preclinical data.

Main Results:

• Metformin influences key pathways like insulin signaling, AMPK, and mTOR, potentially inhibiting EC progression.
• Evidence suggests metformin modulates inflammation, oxidative stress, and angiogenesis.
• Consolidated data supports metformin's potential role in EC pathogenesis and management.

Conclusions:

• Metformin demonstrates multifaceted anti-cancer effects relevant to esophageal cancer.
• Further research and clinical trials are warranted to establish metformin's efficacy as an adjuvant therapy for EC.
• Understanding metformin's mechanisms may lead to improved therapeutic strategies and outcomes for EC patients.